share_log

Tilray Medical Announces Positive Results From Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

Tilray Medical Announces Positive Results From Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

Tilray 医疗宣布了关于口服大麻提取物用于化疗诱导的恶心的研究结果
GlobeNewswire ·  11/07 07:00

SYDNEY, Australia, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, is pleased to announce the final results of a new scientific study their team has supported titled, "Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)."

澳大利亚悉尼,2024年11月7日(环球新闻社)- Tilray Medical,Tilray Brands,Inc.("Tilray Brands")(纳斯达克:TLRY和tsx:TLRY)的一个部门,是医疗大麻股全球领导者,赋予患者和医疗从业者协作进行知情个性化健康决策的权力,很高兴宣布他们团队支持的一项名为"化疗诱发恶心与呕吐的继发预防用口服大麻提取物的新科学研究"的最终结果。

This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.

这项随机、安慰剂对照试验旨在测试口服大麻提取物对尽管接受标准抗恶心治疗仍遭受化疗诱发恶心与呕吐的成年人的有效性。参与者每天服用含有2.5毫克THC和2.5毫克CBD的胶囊,或安慰剂,连续六天,每日三次。

From 2016 to 2022, 147 participants were recruited. The study found that the cannabis extract significantly improved the rate of complete response—meaning no vomiting or use of additional medications—from 8% with placebo to 24% with THC: CBD. Other benefits included reduced nausea and fewer daily vomits. However, some side effects were noted, such as sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%).

从2016年到2022年,共有147名参与者被招募。研究发现,大麻提取物显著提高了完全缓解率(即无呕吐或使用额外药物)从安慰剂的8%到THC:CBD的24%。其他好处包括减少恶心和每日呕吐次数。然而,也有一些副作用,如嗜睡(18% vs. 7%),头晕(10% vs. 0%)和短暂焦虑(4% vs. 1%)。

Denise Faltischek, Chief Strategy Officer, and Head of International at Tilray Brands, said, "These findings are encouraging for cancer patients undergoing chemotherapy. This study is a crucial step in improving patient care and quality of life." She continued, "Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV."

Tilray Brands首席战略官兼国际负责人Denise Faltischek表示:"这些发现对正在接受化疗的癌症患者是鼓舞人心的。该研究对提高患者护理和生活质量至关重要。"她继续说:"我们参与这项研究的行动强调了我们促进医学研究的承诺。积极的结果突显了大麻素用于管理化疗诱发恶心与呕吐的潜力。"

Tilray Medical continues to transform lives by providing access to medical cannabis. Tilray is a leading provider of EU-GMP-certified medical cannabis products in over 20 countries. The company has supported medical trials globally, studying cannabis for various conditions, including pediatric epilepsy, cancer-induced nausea, and PTSD.

Tilray Medical继续通过提供医疗大麻股来改变生活。Tilray是全球领先的医疗大麻股产品供应商,在20多个国家提供欧盟GMP认证的医疗大麻股产品。该公司全球支持医疗大麻股的临床试验,研究用于不同病症的大麻股,包括小儿癫痫、癌症引起的恶心和创伤后应激障碍。

About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.

关于Tilray Medical
Tilray Medical致力于通过安全可靠地获得全球医疗大麻品牌组合(包括Tilray、Aphria、Broken Coast、Symbios和Navcora)改变生命和促进需要医疗援助的病患的尊严。Tilray从最初成为加拿大医疗大麻获得批准的认可制造商之一,到在欧洲建立第一批GMP认证大麻生产设施(最初是在葡萄牙,后来是在德国),成为今天的医疗大麻产品供应商,向全球20多个国家的病患、医生、医院、药房、研究人员和政府提供医疗大麻。

For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.

有关Tilray Medical的更多信息,请访问Tilray Medical Europe、Tilray Medical Canada和Tilray Medical Australia-New Zealand。

About Tilray Brands
Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

关于Tilray Brands
Tilray Brands,Inc.(纳斯达克:TLRY;TSX:TLRY)是一家领先的全球生活方式和消费品公司,在加拿大、美国、欧洲、澳大利亚和拉丁美洲设有业务,正成为大麻、饮料、健康和娱乐交汇处的颠覆性力量,通过连接的时刻提升生活质量。Tilray的使命是成为领先的高端生活方式公司,拥有一系列品牌和创新产品,激发快乐和创造难忘的体验。Tilray前所未有的平台支持着全球20多个国家/地区的40多个品牌,包括全面的大麻产品、以大麻素为基础的食品以及手工饮品。

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

要了解更多如何通过连接时刻提升生活品质的信息,请访问Tilray.com并在所有社交平台上关注@Tilray。

Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company's ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

前瞻性声明
本通讯中的某些非历史事实的陈述构成前瞻信息或前瞻性陈述(统称"前瞻性陈述"),根据加拿大证券法和《1933年修正案证券法》第27A条以及《1934年修正案证券交易法》第21E条的规定,旨在受到这些条款和其他适用法律创设的"安全港"的约束。可以通过诸如"预测"、"未来"、"应该"、"可能"、"使能"、"潜在"、"思考"、"相信"、"预期"、"估计"、"计划"、"期望"、"打算"、"可能"、"项目"、"将"、"会"等词语识别前瞻性陈述,虽然并非所有前瞻性陈述都包含这些标识词。本通讯中包含的前瞻性陈述中涉及的结论中使用了某些实质性因素、估算、目标、预测或假设。前瞻性陈述包括有关我们意图、信念、预测、展望、分析或关于当前期望的声明,涉及内容包括:关于公司业绩和规模的预期,包括Tilray Medical;以及公司扩大向全球患者提供服务的能力,包括通过Tilray Medical的方式。许多因素可能导致实际结果、业绩或成就与任何前瞻性陈述大不相同,公司目前尚未知晓的其他风险和不被公司认为重要的不确定因素也可能导致实际结果或事件与本通讯中包含的前瞻性陈述所表达的有所不同。有关这些风险和其他因素的更详细讨论,请参阅Tilray的最新提交的年度信息表和Tilray向SEC提交并在EDGAR上提供的《10-K年度报告》(以及其他向SEC提交的定期报告)。本通讯中包含的前瞻性陈述截至本通讯日发布,并且公司不承诺公开更新此类前瞻性陈述,除非适用证券法律要求。

For further information:
Tilray Brands: news@tilray.com
Investors: investors@tilray.com

进一步了解:
Tilray Brands:news@tilray.com
投资者: investors@tilray.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发